This is the strongest insider signal possible at SMMT — both the Co-CEO and COO/CFO buying aggressively on the same day with their own cash at a ~$11.7B market cap. Given the company's clinical-stage profile and the historical underperformance of prior neutral/bearish calls, this cluster buy suggests the upcoming pipeline catalyst (likely ivonescimab data or regulatory update) is seen internally as highly value-accretive. Traders should monitor for an imminent press release or clinical data readout.
Price Chart
Executive Summary
Co-CEO Mahkam Zanganeh and COO/CFO Manmeet Singh collectively purchased $1.82M in open-market shares at ~$14.50 on June 4, 2026. This is a strong cluster of insider buying from the two top executives, representing ~0.016% of the $11.7B market cap — trivial in percentage terms but highly significant as a C-suite conviction signal at an all-time-high-ish valuation for this clinical-stage biotech.
Key Financial Metrics
Key Facts
- Co-CEO Mahkam Zanganeh bought 100K shares at $14.60 for $1.46M in an open-market purchase.
- COO/CFO Manmeet Singh bought 25K shares at $14.46 for $361.5K in an open-market purchase.
- Total cluster value: $1.82M, all open-market buys — no non-cash or tax-withholding transactions.
- Both purchases occurred on the same day (June 4, 2026), indicating coordinated or strongly aligned conviction.
- At $11.7B market cap, the total buy value is only ~0.016% of market cap — trivial by proportionality but amplified by C-suite cluster buy literature.
- No 10b5-1 pattern or regular-interval sales detected; these are discretionary open-market purchases.
- Prior reports on SMMT have negative T+20 tracking, but those were neutral/bearish reads; this is the first direct bullish insider buy cluster call.
Financial Impact
$1.82M in insider open-market purchases at ~$14.50/share, representing ~0.016% of market cap — small absolute but rare C-suite cluster buy.
Risk Factors
- The buy value is less than 0.02% of market cap — insiders could be attempting to signal confidence ahead of data, not reflecting material private information.
- Prior SMMT reports have shown poor T+20 tracking for neutral calls; however, this is the first clear bullish buy-cluster read in the history.
- Clinical-stage binary risk remains high regardless of insider sentiment — actual trial results determine the stock, not insider positioning.
- The stock trades at ~$14.50 near or above recent levels; insiders buying at elevated prices is unusual and could be misinterpreted as anchoring bias.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SMMT-1780609536117 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access